Literature DB >> 17339279

Flucytosine therapeutic monitoring: 15 years experience from the UK.

A C Pasqualotto1, S J Howard, C B Moore, D W Denning.   

Abstract

BACKGROUND: There is uniform consensus that flucytosine blood concentrations should be measured to avoid toxicity and ensure adequate efficacy. OBJECTIVES AND METHODS: The purpose of this study was to evaluate all flucytosine levels performed in a regional centre in the UK from October 1991 to May 2006. Concentrations were measured by bioassay.
RESULTS: We reviewed 1071 flucytosine levels in 233 patients, including 33 neonates. Overall, only 20.5% of levels were in the expected therapeutic range. Low levels were observed in 40.5%, of which 5.1% were undetectable levels (<12.5 mg/L). High levels occurred in 38.9%, of which 9.9% were considered potentially toxic (>100 mg/L). High flucytosine levels occurred more frequently amongst neonates, which could be related to an immature renal system resulting in drug accumulation.
CONCLUSIONS: Our findings reveal that the vast majority of patients were out of range for flucytosine levels. These data emphasize the importance of monitoring flucytosine levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339279     DOI: 10.1093/jac/dkl550

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

2.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 3.  Therapeutic drug monitoring for tomorrow.

Authors:  Erik Eliasson; Jonatan D Lindh; Rickard E Malmström; Olof Beck; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 4.  Current concepts in antifungal pharmacology.

Authors:  Russell E Lewis
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

Review 5.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

6.  Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.

Authors:  Celeste Alvarez; David R Andes; Jeong Yeon Kang; Carmen Krug; Glen S Kwon
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

7.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

Review 8.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 9.  Treatment and prophylaxis of invasive candidiasis.

Authors:  Nidhi Tripathi; Kevin Watt; Daniel K Benjamin
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300

10.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.